Abstract:Background Mutiple myeloma (MM) has become the second most prevalent tumor in hematologic diseases, with the age of its onset decreasing year by year. Proteasome inhibitors, immunomodulators and monoclonal antibodies are the most commonly used agents for treating MM. Although the treatment effect and survival time of MM patients has significantly improved with therapies, MM remains an incurable disease, and most MM patients during treatment inevitably undergo primary or secondary drug resistance, leading to disease recurrence and progression, and even death. Therefore, exploring new agents for MM treatment can have significant clinical benefits. CUDC-101 is a multiple inhibitor that directly blocks the HDAC, EGFR and HER2 signaling pathways. In recent years, many studies have shown that CUDC-101 has strong antitumor effects on many tumor types through inducing caspase-dependent apoptosis, regulating proliferation and migration. In addition, CUDC-101 has been reported to exert a synergistic effect with a lot of conventional drugs, for example, Gemcitabine, Arsenic trioxide, or Carfilzomib. However, it was not reported whether CUDC-101 has an anti-myeloma effect or a synergistic effect when applied with other drugs for MM treatment. Methods CCK8 assay was used to detect the inhibitory effect of drugs on the cell proliferation of six human myeloma cell lines. TUNEL assay and Flow cytometry was used to detect the apoptosis and cell cycle. Western bolt was used to detect the expression of apotosis-related proteins and signaling pathway. MM xenografts model was used to indicate the efficacy in vivo. Results In this paper, we identified the potential efficacy of CUDC-101 in MM treatment and elaborated the underlying mechanisms. Our results suggest that CUDC-101 can induce cell cycle arrest to significantly inhibit the proliferation of as well as induce cell apoptosis in MM cell lines or primary CD138 positive MM cells through the inhibition of EGFR/PI3K and HDAC signaling pathways. Meanwhile, CUDC-101 also showed marked growth inhibition in the MM xenografts model. In addition, we confirmed the synergistic effect between CUDC-101 and Bortezomib, one of the drugs most commonly used drugs for MM treatment. Using MM cell lines and xenograft models, we demonstrated the remarkable inhibitive effect of these drugs on cell proliferation and tumor growth. Further investigation revealed that the G2/M phase arrest is a pivotal mechanism to achieve this effect, which involves the upregulation of P21 and P27. And these data prove that CUDC-101 is an effective agent in MM therapy. Conclusion In summary, we have confirmed the efficacy of CUDC-101 in MM treatment as a single drug or in combination with Bortezomib, and our findings offer a new strategy for MM therapy.

Effect of HM910, a Novel Camptothecin Derivative, on the Inhibition of Multiple Myeloma Cell Growth in Vitro and in Vivo.

Homoharringtonine Inhibits the Akt Pathway and Induces in Vitro and in Vivo Cytotoxicity in Human Multiple Myeloma Cells

Camptothecin Nanocolloids Based On N,N,N-Trimethyl Chitosan: Efficient Suppression Of Growth Of Multiple Myeloma In A Murine Model

Identification of a Novel C-Myc Inhibitor 7594-0037 by Structure-Based Virtual Screening and Investigation of Its Anti-Cancer Effect on Multiple Myeloma

Design, Synthesis, Mechanisms of Action, and Toxicity of Novel 20(S)-Sulfonylamidine Derivatives of Camptothecin As Potent Antitumor Agents

DCZ0801, a Novel Compound, Induces Cell Apoptosis and Cell Cycle Arrest Via MAPK Pathway in Multiple Myeloma.

Preclinical Activity Of Dcz3301, A Novel Aryl-Guanidino Compound In The Therapy Of Multiple Myeloma

The novel norcantharidin derivative DCZ5417 suppresses multiple myeloma progression by targeting the TRIP13–MAPK–YWHAE signaling pathway

CC102528: A Novel Histone Deacetylase Inhibitor in the Hydroxamate Family Demonstrates Potent Anti-Myeloma Activity.

Dual Inhibition of Mtorc1/2 by DCZ0358 Induces Cytotoxicity in Multiple Myeloma and Overcomes the Protective Effect of the Bone Marrow Microenvironment

HDAC Inhibitor and BCL2 Selective Inhibitor Synergistically Exert Cytotoxicity on Human Myeloma Cells by Upregulating BIM Expression

CDK5 Inhibition in Vitro and in Vivo Induces Cell Death in Myeloma and Overcomes the Obstacle of Bortezomib Resistance.

A Novel Small Molecule Compound Displays Preclinical Activity Against Multiple Myeloma by Disrupting the Mtor Signaling Pathway

Anti-tumor Effects and Mechanism of a Novel Camptothecin Derivative YCJ100.

Design, synthesis, and biological evaluation of novel 1-amido-2-one-4-thio-deoxypyranose as potential antitumor agents for multiple myeloma

Cmar_a_194202 4797..4808

Antitumor activity and pharmacokinetics following oral administration of natural product DNA topoisomerase I inhibitors 10-hydroxycamptothecin and camptothecin in SCID mice bearing human breast cancer xenografts.

Antitumor Potential of a Novel Camptothecin Derivative, ZBH-ZM-06

Enhanced Precision Therapy of Multiple Myeloma Through Engineered Biomimetic Nanoparticles with Dual Targeting

EGFR and HDAC Dual-Target Inhibitor CUDC-101 Enhances the Anti-Myeloma Effects of Bortezomib by Regulating the G2/M Cell Cycle Arrest

Design and synthesis of novel 7-ethyl-10-fluoro-20-O-(cinnamic acid ester)-camptothecin derivatives as potential high selectivity and low toxicity topoisomerase I inhibitors for hepatocellular carcinoma